It doesn't, and we shouldn't sell at such a discount. Why does everyone assume that's the best thing for the company? Investors should stop capitulating on this issue. What we need, and what we've always needed ever since 48-week results were announced, is to partner with a big pharma.
I'm not saying it's right, but it is what it is, and it's not going to change. Given that, you swallow your pride and you get the big guns on board.
There comes a time when you swallow your pride, and Chris has a hard time doing that. Who suffers the most by all of this nonsense It's not the shareholders. It's the kids who need this drug. Chris needs to stop letting his ego be his primary decision maker.
Let me add that I think he has the children's best interests at heart, but his unwillingness to get help from a big player is causing damage to this company. PARTNER already!
I mean, you seriously deserve to get smacked in that sissy mouth of yours. Hiding behind a computer screen insulting a kid who probably only has a few years left through absolutely no fault of his own. What a waste of space you are.
Time for me to logoff the internet.
Woah, man. I don't mind hearing your points as they are intelligently written, but frankly, WTH is wrong with you for saying something so incredibly horrible as that? Whatever you beef is with SRPT, can't you just keep it to that? Are you really so hateful that you think it's okay to say something like this?
It's more than just that, jrrt1. You're leaving out plenty of pertinent details that are highly relevant to its status as a go-to drug. The drug has been tested in over 1,000 humans, and has had no serious adverse events. In terms of efficacy with regards to the viruses it has been used to treat, it has been quite effective, and in the case of Josh Hardy, is almost certainly responsible for saving his life.
I think your anger is misguided. Instead of hating on Brincidofavir, you should hate on whoever is preventing SRPT's drug from being used. And if you're going to use the argument that it needs more clinical testing in order to be used, then why exactly are you invested in SRPT? Wouldn't that apply here as well?
I'm long both, for what it's worth. I'd be happy to see SRPT's drug used, but I also understand why Brincidofavir has become the go-to, and frankly, I agree with the decision. I probably would even if I wasn't invested in CMRX. (And I've been invested way before Ebola became an issue.)
You're an idiot. The NYC doctor specifically requested CMRX's drug. He probably did that because he knows it won't work and he'd rather die, right? Makes tons of sense.
ch.kemp is right. And I'm long CMRX. I think it's the leader for Ebola treatment. But the headline that she received no experimental drug was all over every major news source. Not hard to find, man. I'll take every major news source over a blog post any day of the week, as would anyone with common sense.
Check NY Daily News: EXCLUSIVE: City health officials desperately search for experimental drug to use on Ebola patient Craig Spencer
Includes an attachment of the email. Been saying for a while now, that Chimerix will emerge as the leader in treatments. They have a huge advantage of TKMR in that their drug is much easier to manufacture because it is a pill, and thus much easier to take. It has also been tested on more than 1,000 patients for other viral conditions and has been found to be safe and effective. The trick is to get the drug to the patient as early as possible. It works by stopping the virus from replicating, which explains why it didn't help the Dallas patient. He received the drug over 10 days after he had been symptomatic, so the virus was already running rampant in his system.
Well, never thought about it like that. I don't believe the company has put a timeline on when they will give an update. But it would make sense that they would expect the patient to be free of symptoms for a significant amount of time before saying anything.
My response was based on what the consensus of analysts seems to be. Personally, I hope it occurs sooner than later. This company is dying to get bought out at a huge premium.
Q1 is a slight possibility since the patient was treated well before the end of the year, but early to mid Q2 is more likely.
Way off. The assumption was that the first patient wouldn't be dosed until December. Even with that assumption, results were expected 1H 2015.
Yeah, I can see that point. He does seem to revel in the idea.
Zwerp, to be fair this is a kind of manipulative statement. I don't agree with pasteur, but there is a difference between "hoping" and "believing". I doubt anyone out there wants DMD boys to suffer further. That being said, pasteur seems to be looking at this through a strict protocol set of eyes. He's ignoring the cost-benefit analysis completely, and on that front, I think that is why he'll be proven wrong. Eteplirsen gets early approval.